Committed to developing novel vaccines against major infectious diseases and public health threats worldwide
Stable and high yield:
Breaks bottlenecks of traditional VLP manufacturing technology
Broad spectrum:
Can be used for rapid development of a wide range of pathogenic vaccines, including emergency products such as COVID vaccine
Stronger efficacy:
Particle presentation improves the immunogenicity of otherwise poorly immunogenic protein antigens, together with steric presentation promotes conserved epitopes recognition thus higher broadly neutralising antibody titers